MFAR

Genitourinary Tumors With Sacituzumab Tirumotecan

Role: collaborator

Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

Role: collaborator

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Role: collaborator

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Role: collaborator

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Role: collaborator

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Role: collaborator

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Role: collaborator

Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)

Role: collaborator

Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

Role: collaborator

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Role: collaborator

CEB-01 in Locally Resectable Pancreatic Cancer

Role: collaborator

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

Role: collaborator

Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Role: collaborator

Sacituzumab govitEcan in THYroid Cancers

Role: collaborator

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Role: collaborator

Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

Role: collaborator